Suppr超能文献

通过高通量筛选鉴定的花色苷对 HER2 阳性乳腺癌细胞的选择性增殖抑制作用。

Selective anti-proliferation of HER2-positive breast cancer cells by anthocyanins identified by high-throughput screening.

机构信息

Department of Scientific Research, First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan Province, China.

出版信息

PLoS One. 2013 Dec 3;8(12):e81586. doi: 10.1371/journal.pone.0081586. eCollection 2013.

Abstract

Overexpressed Human epidermal growth factor receptor 2 (HER2) drives the biology of 20% breast cancer and is a prediction of a poor prognosis for patients. HER2-targeted therapies significantly improve outcomes for HER2-positive patients. Traditional Chinese herbs/medicines have been used to treat breast cancer patients including HER2-positive patients in Asia for decades. Although the traditional medicines demonstrate efficacy in clinics for HER2-positive patients, the mechanism is largely unknown. In this article, we screened a 10,000 natural product library in 6 different cell lines representing breast cancer, and assessed the ability of each drug to cause cytotoxicity through a high-throughput screening approach. We have identified eight natural compounds that selectively inhibit the proliferation of HER2-positive cells. Two of the hit compounds, peonidin-3-glucoside and cyaniding-3-glucoside, are both extracts from black rice. They inhibit the phospho-HER2 and phospho-AKT and were confirmed to induce HER2-psotive breast cancer cells apoptosis both in vitro and in vivo. Peonidin-3-glucoside and cyaniding-3-glucoside treatments significantly reduced the tumor size and volume in vivo compared to the control group. There is no significant difference of antitumorgenic effects between peonidin-3-glucoside and cyaniding-3-glucoside treatments.

摘要

过度表达的人类表皮生长因子受体 2(HER2)驱动了 20%乳腺癌的生物学特性,并且是预测患者预后不良的指标。HER2 靶向治疗显著改善了 HER2 阳性患者的预后。传统中药已被用于治疗亚洲的乳腺癌患者,包括 HER2 阳性患者,已有数十年的历史。尽管传统药物在临床上对 HER2 阳性患者显示出疗效,但机制在很大程度上尚不清楚。在本文中,我们在代表乳腺癌的 6 种不同细胞系中筛选了 10000 种天然产物库,并通过高通量筛选方法评估了每种药物引起细胞毒性的能力。我们已经确定了 8 种天然化合物,它们选择性地抑制 HER2 阳性细胞的增殖。两种命中化合物,矢车菊素-3-葡萄糖苷和矢车菊素-3-芸香糖苷,均来自黑米提取物。它们抑制磷酸化 HER2 和磷酸化 AKT,并被证实可在体外和体内诱导 HER2 阳性乳腺癌细胞凋亡。与对照组相比,矢车菊素-3-葡萄糖苷和矢车菊素-3-芸香糖苷处理显著减少了体内肿瘤的大小和体积。矢车菊素-3-葡萄糖苷和矢车菊素-3-芸香糖苷处理的抗肿瘤作用没有明显差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8df9/3849376/78a9055a9e4d/pone.0081586.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验